Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D0X8MI
|
|||
Former ID |
DIB010051
|
|||
Drug Name |
Berupipam
|
|||
Synonyms |
NNC-22-0010
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Psychotic disorder [ICD-11: 6A20-6A25] | Discontinued in Phase 1 | [1] | |
Company |
Novo Nordisk A/S
|
|||
Structure |
Download2D MOL |
|||
Formula |
C19H19BrClNO2
|
|||
Canonical SMILES |
CN1CCC2=CC(=C(C=C2C(C1)C3=CC(=CC4=C3OCC4)Br)O)Cl
|
|||
InChI |
1S/C19H19BrClNO2/c1-22-4-2-11-7-17(21)18(23)9-14(11)16(10-22)15-8-13(20)6-12-3-5-24-19(12)15/h6-9,16,23H,2-5,10H2,1H3/t16-/m0/s1
|
|||
InChIKey |
DIKLCFJDIZFAOM-INIZCTEOSA-N
|
|||
CAS Number |
CAS 150490-85-0
|
|||
PubChem Compound ID |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Dopamine D1 receptor (D1R) | Target Info | Antagonist | [2] |
KEGG Pathway | Calcium signaling pathway | |||
cAMP signaling pathway | ||||
Neuroactive ligand-receptor interaction | ||||
Gap junction | ||||
Dopaminergic synapse | ||||
Parkinson's disease | ||||
Cocaine addiction | ||||
Amphetamine addiction | ||||
Morphine addiction | ||||
Alcoholism | ||||
Panther Pathway | Dopamine receptor mediated signaling pathway | |||
Pathwhiz Pathway | Dopamine Activation of Neurological Reward System | |||
Reactome | Dopamine receptors | |||
G alpha (s) signalling events | ||||
WikiPathways | Hypothetical Network for Drug Addiction | |||
Monoamine GPCRs | ||||
GPCRs, Class A Rhodopsin-like | ||||
Genes and (Common) Pathways Underlying Drug Addiction | ||||
GPCR ligand binding | ||||
GPCR downstream signaling |
References | Top | |||
---|---|---|---|---|
REF 1 | Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004006) | |||
REF 2 | Characterization of benzazepine UDP-glucuronosyl-transferases in laboratory animals and man. Xenobiotica. 1995 Jun;25(6):611-22. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.